The Food and Drug Administration (FDA) approved a twice-yearly injection developed to prevent HIV.
The first and only of its kind drug, manufactured by Gilead Sciences, will be sold under the name Yeztugo (lenacapavir).
WATCH:
#GileadNews: The FDA has approved our injectable HIV-1 prevention medication, making it the first and only twice-yearly #HIV prevention option in the U.S. This approval is helping to usher in the future of prevention as we work to help end the epidemic. https://t.co/wGacaduPRn pic.twitter.com/BqVToUqrtX
Trending: Smartest Man In World (IQ 276) Says “Jesus Christ Is God”
— Gilead Sciences (@GileadSciences) June 18, 2025
Per Gilead Sciences:
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!